Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/annrheumdis-2016-209166 http://scihub22266oqcxt.onion/10.1136/annrheumdis-2016-209166 C4893105!4893105!26964144     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26964144&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Ann+Rheum+Dis 2016 ; 75 (6): 974-82 Nephropedia Template TP {{tp|p=26964144|t=2016. The changing landscape of biosimilars in rheumatology |pdf=|usr=}}{{26964144}} gab.com Text The changing landscape of biosimilars in rheumatology JO: Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=26964144 #FOAvip Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval. Twit Text FOAVip The changing landscape of biosimilars in rheumatology ????Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=26964144 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26964144 #FOAvip English Wikipedia <ref>{{Cite pmid|26964144}}</ref> The changing landscape of biosimilars in rheumatology #MMPMID26964144 Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR Ann Rheum Dis 2016[Jun]; 75 (6): 974-82 PMID26964144show ga Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic potential offered by these agents. Notably, rheumatologists will be at the forefront of the use of biosimilar monoclonal antibodies/soluble receptors. Biosimilars offer cost savings and health gains for our patients and will play an important role in treating rheumatic diseases. We hope that these lower costs will compensate for inequities in access to therapy based on economic differences across countries. Since approved biosimilars have already demonstrated highly similar efficacy, it will be most important to establish pharmacovigilance databases across countries that are adequate to monitor long-term safety after marketing approval. äThe changing landscape of biosimilars in rheumatology (epmc).pdf DeepDyve Pubget Overpricing